Efranat's Series A Round

Efranat raised a round of funding on November 18, 2014.

Efranat develops a unique anti-cancer immunotherapy treatment based on a natural plasma protein molecule named GcMAF. The concept underlying the technology is to engage the body's own immune system an…

Articles about Efranat's Series A Round: